These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23176724)

  • 41. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
    Barlogie B; Anaissie E; Haessler J; van Rhee F; Pineda-Roman M; Hollmig K; Alsayed Y; Epstein J; Shaughnessy JD; Crowley J
    Cancer; 2008 Jul; 113(2):355-9. PubMed ID: 18470907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1206-12. PubMed ID: 11579631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
    Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
    Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Problems in the treatment of multiple myeloma].
    Shimizu K
    Rinsho Ketsueki; 1997 Apr; 38(4):302-5. PubMed ID: 9146056
    [No Abstract]   [Full Text] [Related]  

  • 45. Advances in the treatment of multiple myeloma.
    Barlogie B; Jagannath S; Tricot G; Desikan KR; Fassas A; Siegel D
    Adv Intern Med; 1998; 43():279-320. PubMed ID: 9506186
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of multiple myeloma].
    Tokumine H; Machii T; Kitani T
    Nihon Naika Gakkai Zasshi; 1995 Jul; 84(7):1100-6. PubMed ID: 7561366
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
    Tousková M; Maisnar V; Krejsek J; Kopecký O
    Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
    Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
    Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple myeloma in younger age.
    Akhtar K; Laghari NA; Haq AU; Anees M; Rehman SU; Alam MI
    J Coll Physicians Surg Pak; 2009 Jan; 19(1):62-3. PubMed ID: 19149986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma: new aspects of biology and treatment.
    Ozaki S; Kosaka M
    J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
    Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
    Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
    Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
    Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained minimal residual disease in myeloma.
    Bianchi G
    Blood; 2022 Jan; 139(4):469-471. PubMed ID: 35084473
    [No Abstract]   [Full Text] [Related]  

  • 55. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.
    Van Oekelen O; Birrer N; Wesson W; Galate VL; Cliff ERS; Goodman AM; Abdallah AO; Chakraborty R; Prasad V; Mohyuddin GR
    Blood Cancer J; 2022 Nov; 12(11):155. PubMed ID: 36379917
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiple myeloma.
    Zulian GB; Babare R; Zagonel V
    Crit Rev Oncol Hematol; 1998 Feb; 27(2):165-7. PubMed ID: 9571324
    [No Abstract]   [Full Text] [Related]  

  • 57. Optimizing multiple myeloma treatment: conclusions.
    Palumbo A
    Leuk Res; 2012 Nov; 36 Suppl 1():S44-5. PubMed ID: 23176724
    [No Abstract]   [Full Text] [Related]  

  • 58. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
    Moreau P; Giralt SA
    Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Initial therapy for multiple myeloma].
    Shimizu K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():589-96. PubMed ID: 23134020
    [No Abstract]   [Full Text] [Related]  

  • 60. Frontline therapy in multiple myeloma: fast start for a long game.
    Patriarca F
    Lancet Haematol; 2019 Dec; 6(12):e600-e601. PubMed ID: 31624046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.